Cell therapy for diabetes: New data, approval, buyout; GLP-1 race in weight loss reaches new stage; FDA finally approves BioMarin’s gene therapy; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
For many of our US readers, this may be the start of a long weekend as we look ahead to the holiday on July 4. A scheduling note: On Monday, July 3, we won’t publish our early edition, but our early and later afternoon newsletters will still be arriving in your inboxes. Have a good weekend.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.